Search results for: “MYL”

  • Mylan NV Valuation – March 2019 #MYL

    Mylan NV Valuation – March 2019 #MYL

    Mylan NV does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, poor dividend history.

  • Mylan NV Valuation – June 2018 $MYL

    Mylan NV Valuation – June 2018 $MYL

    Mylan NV does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, poor dividend history.

  • Mylan NV Valuation – March 2017 $MYL

    Mylan NV Valuation – March 2017 $MYL

    Mylan N.V. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability or growth over the last ten years, and the poor dividend history.

  • Mylan NV Valuation – January 2016 Update $MYL

    Mylan NV Valuation – January 2016 Update $MYL

    Mylan NV does not qualify for either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability in the last ten years, lack of dividends, and the high PEmg and PB ratios.

  • Mylan Inc. Annual Valuation – 2014 $MYL

    Mylan Inc. Annual Valuation – 2014 $MYL

    Mylan Inc. is not suitable for either the Defensive Investor or the Enterprising Investor. The Defensive Investor is concerned by the low current ratio, the lack of earnings stability over the last ten years, lack of dividend payments and the high PEmg and PB ratios.

  • Johnson & Johnson Valuation – April 2019 #JNJ

    Johnson & Johnson Valuation – April 2019 #JNJ

    Johnson & Johnson does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings growth over the last ten years, and the high PEmg and PB ratios.

  • Bristol-Myers Squibb Co Valuation – April 2019 #BMY

    Bristol-Myers Squibb Co Valuation – April 2019 #BMY

    Bristol-Myers Squibb Co is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, high PB ratio.

  • Biogen Inc Valuation – March 2019 #BIIB

    Biogen Inc Valuation – March 2019 #BIIB

    Biogen Inc qualifies for both the Defensive Investor and the Enterprising Investor. The Defensive Investor is only initially concerned with the poor dividend history.

  • Pfizer Inc Valuation – November 2018 $PFE

    Pfizer Inc Valuation – November 2018 $PFE

    Pfizer Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, high PEmg and PB ratios.

  • Nektar Therapeutics Valuation – November 2018 $NKTR

    Nektar Therapeutics Valuation – November 2018 $NKTR

    Nektar Therapeutics does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.